Preparation and in vitro evaluation of meloxicam-loaded PLGA nanoparticles on HT-29 human colon adenocarcinoma cells

Drug Development and Industrial Pharmacy

Volumn 38, Issue 9, 2012, Pages 1107-1116

  Şengel Türk, C Tuba ^a   Hasçiçek, Canan ^a   Dogan, A Lale ^b   Esendagli, Gunes ^b   Guc, Dicle ^b   Gönül, Nurşin ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Cyclooxygenase 2; Cytotoxicity; Nanoparticles; PLGA; PVA; Uptake

Indexed keywords

CYCLOOXYGENASE 2; MELOXICAM; NANOPARTICLE; POLYGLACTIN;

ARTICLE; CANCER CELL; CARCINOMA CELL; CELL VIABILITY; COLON ADENOCARCINOMA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG SCREENING; DRUG SYNTHESIS; EMULSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR WEIGHT; NANOENCAPSULATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; ZETA POTENTIAL;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; COLONIC NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; DRUG CARRIERS; DRUG STABILITY; HT29 CELLS; HUMANS; KINETICS; LACTIC ACID; MOLECULAR WEIGHT; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; POLYVINYL ALCOHOL; SOLUBILITY; SURFACE PROPERTIES; THIAZINES; THIAZOLES;

EID: 84864441657     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.641562     Document Type: Article

References (49)

1. Jain A, Jain SK, Ganesh N, Barve J, Beg AM. (2010). Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer. Nanomedicine, 6:179-190.
2. Brambilla G, Martelli A. (2009). Genotoxicity and carcinogenicity studies of analgesics, anti-inflammatory drugs and antipyretics. Pharmacol Res, 60:1-17.
3. Deorukhkar A, Krishnan S. (2010). Targeting inflammatory pathways for tumor radiosensitization. Biochem Pharmacol, 80:1904-1914.
4. Naruse T, Nishida Y, Ishiguro N. (2007). Synergistic effects of meloxicam and conventional cytotoxic drugs in human MG-63 osteosarcoma cells. Biomed Pharmacother, 61:338-346.
5. Tsai CS, Luo SF, Ning CC, Lin CL, Jiang MC, Liao CF. (2009). Acetylsalicylic acid regulates MMP-2 activity and inhibits colorectal invasion of murine B16F0 melanoma cells in C57BL/6J mice: Effects of prostaglandin F(2)a. Biomed Pharmacother, 63:522-527.
6. Wu WK, Sung JJ, Lee CW, Yu J, Cho CH. (2010). Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: An up date on the molecular mechanisms. Cancer Lett, 295:7-16.
7. Hyde CA, Missailidis S. (2009). Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumourangiogenesis. Int Immunopharmacol, 9:701-715.
8. Sakagami H. (2010). Apoptosis-inducing activity and tumorspecificity of antitumor agents against oral squamous cell carcinoma. Japan Dent Sci Rev, 46:173-187.
9. Suzuki R, Yamamoto M, Saka H, Taniguchi H, Shindoh J, Tanikawa Y et al. (2009). A phase II study of carboplatin and paclitacel with meloxicam. Lung Cancer, 63:72-76.
10. Dong X, Ke X, Liao Z. (2011). The microstructure characterization of meloxicam microemulsion and its influence on the solubilization capacity. Drug Dev Ind Pharm, 37:894-900.
11. Patel M, Joshi A, Hassanzadeth H, Juluru R, Stagni G. (2011). Quantification of dermal and transdermal delivery of meloxicam gels in rabbits. Drug Dev Ind Pharm, 37:613-617.
12. Goldman AP, Williams CS, Sheng H, Lamps LW, Williams VP, Pairet M et al. (1998). Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis, 19:2195-2199.
13. Tsubouchi Y, Mukai S, Kawahito Y, Yamada R, Kohno M, Inoue K et al. (2000). Meloxicam inhibits the growth of non-small cell lung cancer. Anticancer Res, 20:2867-2872.
14. Kern MA, Schöneweiss MM, Sahi D, Bahlo M, Haugg AM, Kasper HU et al. (2004). Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis, 25:1193-1199.
15. Montejo C, Barcia E, Negro S, Fernández-Carballido A. (2010). Effective antiproliferative effect of meloxicam on prostate cancer cells: Development of a new controlled release system. Int J Pharm, 387:223-229.
16. Hattori K, Iida K, Joraku A, Tsukamoto S, Akaza H, Oyasu R. (2006). Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis. BJU Int, 97:640-643.
17. Naruse T, Nishida Y, Hosono K, Ishiguro N. (2006). Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. Carcinogenesis, 27:584-592.
18. Wolfesberger B, Walter I, Hoelzl C, Thalhammer JG, Egerbacher M. (2006). Antineoplastic effect of the cyclooxygenase inhibitor meloxicam on canine osteosarcoma cells. Res Vet Sci, 80:308-316.
19. Acharya S, Sahoo SK. (2011). PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev, 63:170-183.
20. He C, Hu Y, Yin L, Tang C, Yin C. (2010). Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials, 31:3657-3666.
21. Wang M, Thanou M. (2010). Targeting nanoparticles to cancer. Pharmacol Res, 62:90-99.
22. Malam Y, Loizidou M, Seifalian AM. (2009). Liposomes and nanoparticles: Nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci, 30:592-599.
23. Song X, Zhao Y, Hou S, Xu F, Zhao R, He J et al. (2008b). Dual agents loaded PLGA nanoparticles: Systematic study of particle size and drug entrapment efficiency. Eur J Pharm Biopharm, 69:445-453.
24. Birnbaum DT, Kosmala JD, Brannon-Peppas L. (2000). Optimization of preparation techniques for poly(lactic acid-coglycolic acid) nanoparticles. J Nanopart Res, 2:173-181.
25. Katsikari A, Patronidou C, Kiparissides C, Arsenakis M. (2009). Uptake and cytotoxicity of poly(D,L-lactide-co-glycolide) nanoparticles in human colon adenocarcinoma cells. Mat Sci Eng B, 165:160-164.
26. Kumari A, Yadav SK, Yadav SC. (2010). Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces, 75:1-18.
27. Shi K, Cui F, Yamamoto H, Kawashima Y. (2009). Optimized formulation of high-payload PLGA nanoparticles containing insulin-lauryl sulfate complex. Drug Dev Ind Pharm, 35:177-184.
28. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S. (2002). Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett, 531:278-284.
29. Zhang N, Tao K, Huang T. (2007). Effects of meloxicam on vascular endothelial growth factor and angiopoietin-2 expression in colon carcinoma cell line HT-29. J Huazhong Univ Sci Technol Med Sci, 27:399-402.
30. Gao C, Huang J, Jiao Y, Shan L, Liu Y, Li Y et al. (2006). In vitro release and in vivo absorption in beagle dogs of meloxi cam from Eudragit FS 30 D-coated pellets. Int J Pharm, 322: 104-112.
31. McCarron PA, Donnelly RF, Marouf W. (2006). Celecoxib-loaded poly(D,L-lactide-co-glycolide) nanoparticles prepared using a novel and controllable combination of diffusion and emulsification steps as part of the salting-out procedure. J Microencapsul, 23:480-498.
32. Budhian A, Siegel SJ, Winey KI. (2007). Haloperidol-loaded PLGA nanoparticles: Systematic study of particle size and drug content. Int J Pharm, 336:367-375.
33. Klose D, Siepmann F, Elkharraz K, Siepmann J. (2008). PLGA-based drug delivery systems: Importance of the type of drug and device geometry. Int J Pharm, 354:95-103.
34. Sengel CT, Hasçiçek C, Gönül N. (2006). Development and in vitro evaluation of modified release tablets including ethylcellulose microspheres loaded with diltiazem hydrochloride. J Microencapsul, 23:135-152.
35. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. (2002). Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release, 82:105-114.
36. Bayindir ZS, Yuksel N. (2010). Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery. J Pharm Sci, 99:2049-2060.
37. Greulich C, Diendorf J, Simon T, Eggeler G, Epple M, Köller M. (2011). Uptake and intracellular distribution of silver nanoparticles in human mesenchymal stem cells. Acta Biomater, 7:347-354.
38. Mittal G, Sahana DK, Bhardwaj V, Ravi Kumar MN. (2007). Estradiol loaded PLGA nanoparticles for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Control Release, 119:77-85.
39. Song X, Zhao Y, Wu W, Bi Y, Cai Z, Chen Q et al. (2008a). PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: Systematic study of particle size and drug entrapment efficiency. Int J Pharm, 350:320-329.
40. Danhier F, Lecouturier N, Vroman B, Jérôme C, Marchand-Brynaert J, Feron O et al. (2009). Paclitaxel-loaded PEGylated PLGA-based nanoparticles: In vitro and in vivo evaluation. J Control Release, 133:11-17.
41. Zhang Z, Feng SS. (2006). Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: Synthesis, formulation, characterization and in vitro drug release. Biomaterials, 27:262-270.
42. Konan YN, Gurny R, Allémann E. (2002). Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. Int J Pharm, 233:239-252.
43. Panyam J, Dali MM, Sahoo SK, Ma W, Chakravarthi SS, Amidon GL et al. (2003). Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles. J Control Release, 92:173-187.
44. Hong K, Nakayama K, Park S. (2002). Effects of protective colloids on the preparation of poly(l-lactide)/poly(butylene succinate) microcapsules. Eur Polym J, 38:305-311.
45. Liu Y, Pan J, Feng SS. (2010). Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: Effects of surfactants on particles size, characteristics and in vitro performance. Int J Pharm, 395:243-250.
46. Tahara K, Sakai T, Yamamoto H, Takeuchi H, Hirashima N, Kawashima Y. (2009). Improved cellular uptake of chitosan-modified PLGA nanospheres by A549 cells. Int J Pharm, 382:198-204.
47. Yan F, Zhang C, Zheng Y, Mei L, Tang L, Song C et al. (2010). The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity. Nanomedicine, 6:170-178.
48. Cegnar M, Premzl A, Zavasnik-Bergant V, Kristl J, Kos J. (2004). Poly(lactide-co-glycolide) nanoparticles as a carrier system for delivering cysteine protease inhibitor cystatin into tumor cells. Exp Cell Res, 301:223-231.
49. Davda J, Labhasetwar V. (2002). Characterization of nanoparticle uptake by endothelial cells. Int J Pharm, 233:51-59.